Skip to Content

    Over the past year, Hengrui, China’s largest pharma company, has received half-a-dozen approvals from the FDA, giving global sales at the generic- and innovative-drugs manufacturer a boost—and increasing confidence at home, where drug-contamination scares have left patients skeptical about the industry. Revenue in the first half of 2018 grew 22%, to $1.12 billion. Hengrui is also China’s market leader in oncological treatments, where demand is growing fast as the population grays. Its new-drug pipeline should help growth average 26% over the next two years.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score3.4
    Sector
    Health Care
    Industry
    Pharmaceuticals
    CEO
    Zhou Yun Shu
    Websitehttp://www.hrs.com.cn
    Employees14,864
    HQ Location
    Lianyungang, China
    Revenues ($M) (Past 12 Months)$2,305
    Profits ($M) (Past 12 Months)$547
    Market Value as of Oct. 10, 2018 ($M)$30,922